Portal de Periódicos da CAPES

500P The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)

2023; Elsevier BV; Volume: 34; Linguagem: Inglês

10.1016/j.annonc.2023.10.575

1569-8041

Hidehito Horinouchi, Megumi Furuta, Isao Yokota, Taihei Yamaguchi, Sakiko Itoh, Tomoya Fukui, Akira Iwashima, Yosuke Kawashima, Yoshiko Miura, Hiroshi Tanaka, Taichi Miyawaki, Hiroshi Yokouchi, Keita Miura, R. Saito, Hiroyuki Suzuki, Toshiro Kamoshida, U. Uchinami, Tadafumi Kato, K. Kobayashi, Hajime Asahina,

Cancer Immunotherapy and Biomarkers

There is no standard therapeutic strategy for locoregional recurrence of non-small cell lung cancer (NSCLC) after complete resection. We evaluated the effectiveness and safety of chemoradiotherapy (CRT) followed by durvalumab compared with CRT alone in patients with this disease. We retrospectively collected the data of patients with NSCLC diagnosed with locoregional recurrence after complete resection and subsequently underwent concurrent CRT followed by durvalumab (CRT-D group) or CRT (CRT group) initiated between January 1, 2016 and December 31, 2020. In CRT group, radiotherapy must have been completed by April 30, 2018 to exclude patients who underwent CRT alone after durvalumab approval. Inverse probability treatment weighting (IPTW) was used for survival analysis to adjust baseline characteristics between two groups. The primary outcome was progression-free survival (PFS) from the time of CRT initiation. Among the 196 patients included, 121 patients were in the CRT-D group and 75 patients were in the CRT group; median age 67/68 years; male 64.5%/70.7%; smoker 75.2%/81.3%; PS 0-1 98.3%/100%; Adenocarcinoma 69.4%/72.0%; EGFR mutation 21.5%/23.9%; in patients with known PD-L1 status, PD-L1 ≥50%; 31.9%/36.1%, 1-49%; 40.2%/41.6%, <1%; 27.8%/22.2%. IPTW-adjusted median PFS and OS showed significant improvements with CRT-D group vs CRT group (Table). Grade 3 or 4 adverse events occurred in 48.8% during CRT and 10.7% after the start of durvalumab maintenance in the CRT-D group, and 57.3% in the CRT group; Any-grade pneumonitis occurred in 9.9%, 63.6% and 41.3%, respectively.Table: 500PCRT-D group (n = 119)CRT group (n = 111)IPTW-adjusted PFS median, mo (95% CI)25.4 (16.4-NA)11.5 (7.9-13.8)HR 0.44, 95% CI, 0.30-0.64; P < 0.001IPTW-adjusted OS median, mo (95% CI)NA (NA-NA)NA (32.4-NA)HR 0.49, 95% CI, 0.24-0.99; P = 0.041 Open table in a new tab In our study, PFS and OS in the CRT-D group was significantly longer than in the CRT group. CRT followed by durvalumab is one of the promising treatment strategies for locoregional recurrence of NSCLC after complete resection.